CANF (Can Fite Biopharma) Other Current Payables: $0.00 Mil (As of Dec. 2025)


CANF Can Fite Biopharma Ltd CANF
55 GF Score
Price $2.92
GF Value $5.68
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Other Current Payables?

Can Fite Biopharma CANF +6.18% 55 Other Current Payables is $0.00 Mil as of Dec. 2025. GuruFocus rates CANF with a GF Score™ of 55/100 and a GF Value™ of $5.68 (Possible Value Trap). The stock has 4 warning signs investors should review.

Can Fite Biopharma's Other Current Payables for the quarter that ended in Dec. 2025 was $0.00 Mil.

Can Fite Biopharma's quarterly Other Current Payables increased from Dec. 2024 ($0.00 Mil) to Jun. 2025 ($0.51 Mil) but then declined from Jun. 2025 ($0.51 Mil) to Dec. 2025 ($0.00 Mil).

Can Fite Biopharma Other Current Payables Related Terms

Can Fite Biopharma Other Current Payables Historical Data

* Premium members only.

The historical data trend for Can Fite Biopharma's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Can Fite Biopharma Other Current Payables Chart

Can Fite Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Can Fite Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.43 0.00 0.51 0.00
CANF
55GF Score
Can Fite Biopharma Ltd CANF
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Can Fite Biopharma Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
Can Fite Biopharma (CANF) has a Other Current Payables of $0.00 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Can Fite Biopharma and its competitors.
Is Can Fite Biopharma's Other Current Payables too high?
Can Fite Biopharma's current Other Current Payables is $0.00 Mil. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Other Current Payables compare to VRTX and REGN?
Can Fite Biopharma's Other Current Payables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Can Fite Biopharma and its competitors. Can Fite Biopharma's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.68, compared to a current price of $2.92 — trading 48.6% below its estimated fair value. The current Other Current Payables is $0.00 Mil. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Other Current Payables is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Can Fite Biopharma (CANF) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of $2.92 is trading 48.6% below its estimated GF Value™ of $5.68. GuruFocus considers Can Fite Biopharma to be Possible Value Trap.

Key valuation signals for CANF:

  • Other Current Payables: $0.00 Mil
  • GF Value™: $5.68 vs. price of $2.92 (48.6% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Can Fite Biopharma Business Description

Other Exchanges CANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score

Get the complete analysis for CANF

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.92
Price
$5.68
GF Value